NASDAQ · ALNY
Healthcare · Biotechnology
$237.10
Up+$0.54 (+0.23%)
Updated Aug 31, 2026, 12:11 PM
SID Score
5.0/10
Composite research score
Smart Money
60/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ALNY closed at $237.10 after 20 trading sessions, up 7.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $224.465 | $239.08 | $223.61 | $237.10 | 1.85M |
| Aug 27, 2026 | $236.56 | $238.00 | $230.455 | $236.56 | 1.29M |
| Aug 26, 2026 | $238.54 | $242.89 | $236.60 | $239.00 | 1.12M |
| Aug 25, 2026 | $236.56 | $240.67 | $235.411 | $240.08 | 1.58M |
| Aug 24, 2026 | $235.83 | $237.905 | $228.59 | $236.01 | 2.14M |
| Aug 21, 2026 | $228.88 | $238.97 | $228.34 | $236.22 | 1.91M |
| Aug 20, 2026 | $239.00 | $240.88 | $228.74 | $229.30 | 1.7M |
| Aug 19, 2026 | $234.36 | $244.03 | $233.40 | $242.61 | 1.88M |
| Aug 18, 2026 | $226.27 | $230.91 | $222.01 | $228.61 | 1.6M |
| Aug 17, 2026 | $225.76 | $227.99 | $222.12 | $224.60 | 1.54M |
| Aug 14, 2026 | $223.52 | $228.98 | $220.23 | $228.65 | 1.53M |
| Aug 13, 2026 | $225.95 | $227.54 | $222.70 | $227.12 | 1.45M |
| Aug 12, 2026 | $219.00 | $224.66 | $219.00 | $223.95 | 1.62M |
| Aug 11, 2026 | $217.41 | $223.44 | $216.50 | $221.20 | 1.44M |
| Aug 10, 2026 | $218.00 | $223.4975 | $215.61 | $216.98 | 1.4M |
| Aug 7, 2026 | $217.31 | $219.64 | $210.49 | $219.20 | 1.74M |
| Aug 6, 2026 | $228.58 | $234.00 | $212.9775 | $216.12 | 2.27M |
| Aug 5, 2026 | $221.74 | $229.6499 | $221.5012 | $228.72 | 2.73M |
| Aug 4, 2026 | $220.33 | $222.585 | $215.07 | $219.00 | 3.11M |
| Aug 3, 2026 | $208.035 | $220.49 | $208.035 | $220.33 | 3.4M |
The latest Smart Investors Daily articles mentioning ALNY.
ALNY research
Company profile and research snapshot.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 14, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 4, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 4, 2026 | Truist Securities | Buy | — |
| Aug 3, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on an annualized basis producing an average annual return of 15.09%. Currently, Alnylam Pharmaceuticals has a market
Benzinga · Aug 24, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
Yahoo · Aug 20, 2026
The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.
Benzinga · Aug 20, 2026
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALNY.
